Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2019

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2019

  • December 2019 •
  • 104 pages •
  • Report ID: 4545113 •
  • Format: PDF
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2019

Summary
According to the recently published report ’Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2019’; Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 30 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes.

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity.

The report ’Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2019’ outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 6, 4 and 14 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Ophthalmology, Metabolic Disorders, Respiratory, Gastrointestinal, Hematological Disorders, Infectious Disease, Oncology, Central Nervous System, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones, Immunology and Musculoskeletal Disorders which include indications Glaucoma, Ocular Hypertension, Pulmonary Arterial Hypertension, Diabetic Nephropathy, Diastolic Heart Failure, Open-Angle Glaucoma, Sickle Cell Disease, Acute Heart Failure, Acute Respiratory Distress Syndrome, Alzheimer’s Disease, Chronic Kidney Disease (Chronic Renal Failure), Chronic Thromboembolic Pulmonary Hypertension, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Cystic Fibrosis, Diabetic Foot Ulcers, Duchenne Muscular Dystrophy, Inflammation, Ischemic Stroke, Liver Diseases, Liver Fibrosis, Lung Disease, Mycobacterium Infections, Non-Alcoholic Steatohepatitis (NASH), Onychomycosis (Tinea Unguium), Osteoporosis, Pancreatic Cancer, Prostate Cancer, Pulmonary Hypertension, Stroke, Systolic Heart Failure, Tinea Pedis (Athlete Foot), Vascular Dementias, Vaso-Occlusive Crisis Associated With Sickle Cell Disease and Wounds.

Scope
- The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
- The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.